降胆固醇药物对神经认知功能的影响:系统审查和元分析
Kaiwei Li1,2, Ying Li3, Xia Jiang3
1Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China.
Frontiers in neurology
|February 20, 2026
概括
降胆固醇药物,包括他类药物,不会对神经认知功能产生负面影响或增加不良事件. 降低LDL胆固醇对大脑健康是安全的.
科学领域:
- 心血管药理学心血管药理学
- 神经科学是一个神经科学.
- 临床试验和证据综合
背景情况:
- 神经认知功能对于日常生活至关重要.
- 人们对降胆固醇药物对认知的潜在不良影响存在担忧.
- 了解这些药物对大脑的影响对于患者护理至关重要.
研究的目的:
- 研究降胆固醇药物对神经认知功能的影响.
- 为了确定这些药物是否会增加神经认知事件的风险.
- 综合关于这个主题随机对照试验的证据.
主要方法:
- 在PubMed,Embase和Cochrane图书馆的系统文献搜索到2023年3月,在ClinicalTrials.gov的系统文献搜索到2024年1月.
- 包括随机对照试验评估神经认知结果与降胆固醇药物 (他类药物,ezetimibe,PCSK9抑制剂).
- 独立的数据提取和质量评估,并使用随机效应模型进行元分析.
主要成果:
- 对42项涉及150,405名参与者的研究分析发现,神经认知事件的风险没有增加 (RR:0.99,95% CI:0.88-1.12).
- 按药物类别 (他类药物,埃泽提米布,PCSK9抑制剂) 进行的子组分析显示,风险没有增加.
- 在五个领域 (注意力,精神运动速度,执行功能,工作记忆,记忆) 或全球认知中没有观察到神经认知功能的显著变化.
结论:
- 降胆固醇药物,包括他类药物,胆固醇吸收抑制剂和PCSK9抑制剂,不会对神经认知功能产生不利影响.
- 降低低密度脂蛋白胆固醇水平与神经认知性能下降无关.
- 目前的证据支持这些药物对大脑健康的安全性.
相关概念视频
Drugs Affecting Neurotransmitter Synthesis
2.5K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.5K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
926
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
926
Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Cholesterol: Significance and Regulation
2.1K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
2.1K
Pharmacodynamics in Geriatric Patients: Effects of Age
367
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
367


